Scientific Name: Ibrutinib
Brand Name: Imbruvica
Company Owner: Not Available
Mechanism Of Action Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK) . It forms a covalent bond with a cysteine residue in the active site of BTK (Cys481) , leading to its inhibition. The inhibition of BTK plays a role in the B-cell receptor signaling and thus, the presence of ibrutinib prevents the phosphorylation of downstream substrates such as PLC-γ.
Description of the Drug: Ibrutinib is an antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s Macroglobulinemia.
Protein Data Bank:
Source: DrugBank Online – Retrieved 2023-01-23 from